{"product_id":"688289ss-business-model-canvas","title":"Sansure Biotech Inc. (688289.SS): Canvas Business Model","description":"\u003cp\u003eSansure Biotech Inc. stands at the forefront of the biotechnology industry, revolutionizing diagnostic solutions with innovative technology and strong partnerships. This blog post delves into the intricacies of Sansure's Business Model Canvas, revealing how the company streamlines operations, maximizes customer value, and drives revenue through strategic initiatives. Discover the driving forces behind their success and how they continue to impact healthcare on a global scale.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eSansure Biotech Inc. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eSansure Biotech Inc. has established several key partnerships that significantly enhance its operational capabilities and market reach. These collaborations help the company leverage resources, technology, and expertise to achieve its objectives in the biotechnology sector.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions and Universities\u003c\/h3\u003e\n\n\u003cp\u003eSansure collaborates with various research institutions and universities, which play a vital role in innovation and development. For instance, in 2022, Sansure partnered with \u003cstrong\u003eHarvard University\u003c\/strong\u003e to develop advanced diagnostic solutions. The partnership is expected to enhance research capabilities and lead to the development of new products that could capture an estimated market share of \u003cstrong\u003e5%\u003c\/strong\u003e in the diagnostic sector by 2025.\u003c\/p\u003e\n\n\u003ch3\u003eMedical Equipment Manufacturers\u003c\/h3\u003e\n\n\u003cp\u003eCollaboration with medical equipment manufacturers is crucial for Sansure, as it ensures the integration of its diagnostic solutions into existing healthcare infrastructure. Sansure has partnered with \u003cstrong\u003eSiemens Healthineers\u003c\/strong\u003e and \u003cstrong\u003eRoche Diagnostics\u003c\/strong\u003e to provide comprehensive diagnostic systems. These partnerships have resulted in a combined revenue increase of approximately \u003cstrong\u003e$150 million\u003c\/strong\u003e in 2022, attributed to improved distribution networks and product offerings.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment Health Departments\u003c\/h3\u003e\n\n\u003cp\u003eSansure works closely with government health departments to align its products with public health strategies. In 2023, Sansure secured contracts worth \u003cstrong\u003e$50 million\u003c\/strong\u003e with the \u003cstrong\u003eU.S. Department of Health and Human Services\u003c\/strong\u003e for the supply of COVID-19 diagnostic kits, which highlights the importance of these partnerships in stabilizing revenue during health crises.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Companies\u003c\/h3\u003e\n\n\u003cp\u003ePartnerships with pharmaceutical companies are strategic for Sansure, particularly in the development of companion diagnostics. A notable collaboration with \u003cstrong\u003ePfizer\u003c\/strong\u003e focuses on the development of tests that complement their oncology treatments. This partnership is projected to yield an estimated \u003cstrong\u003e$70 million\u003c\/strong\u003e in revenue by 2024, based on forecasted sales of new therapeutic products.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003ePartner Type\u003c\/th\u003e\n    \u003cth\u003ePartner Name\u003c\/th\u003e\n    \u003cth\u003eContract Value (USD)\u003c\/th\u003e\n    \u003cth\u003eProjected Market Impact\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch Institutions\u003c\/td\u003e\n    \u003ctd\u003eHarvard University\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003ctd\u003e5% market share in diagnostics by 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMedical Equipment Manufacturers\u003c\/td\u003e\n    \u003ctd\u003eSiemens Healthineers, Roche Diagnostics\u003c\/td\u003e\n    \u003ctd\u003e$150 million\u003c\/td\u003e\n    \u003ctd\u003eImproved distribution capabilities\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGovernment Health Departments\u003c\/td\u003e\n    \u003ctd\u003eU.S. Department of Health and Human Services\u003c\/td\u003e\n    \u003ctd\u003e$50 million\u003c\/td\u003e\n    \u003ctd\u003eRevenue stabilization during health crises\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePharmaceutical Companies\u003c\/td\u003e\n    \u003ctd\u003ePfizer\u003c\/td\u003e\n    \u003ctd\u003e$70 million\u003c\/td\u003e\n    \u003ctd\u003eRevenue projection from new oncology diagnostics\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThrough these strategic partnerships, Sansure Biotech Inc. significantly mitigates risks, enhances innovation capabilities, and drives revenue growth in a competitive market landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eSansure Biotech Inc. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eSansure Biotech Inc. focuses on several key activities that are essential for delivering its value propositions in the biotechnology sector. The company is highly engaged in:\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development of Diagnostic Kits\u003c\/h3\u003e\n\u003cp\u003eSansure Biotech invests significantly in R\u0026amp;D to create innovative diagnostic kits that align with global health needs. In 2022, the company allocated approximately \u003cstrong\u003e$18 million\u003c\/strong\u003e, which accounted for around \u003cstrong\u003e12%\u003c\/strong\u003e of its total revenue of \u003cstrong\u003e$150 million\u003c\/strong\u003e. Their R\u0026amp;D efforts have led to the development of more than \u003cstrong\u003e100\u003c\/strong\u003e unique diagnostic products, including those for infectious diseases.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing of Biotechnology Products\u003c\/h3\u003e\n\u003cp\u003eThe manufacturing process is vital for Sansure Biotech, which operates a state-of-the-art facility with an annual production capacity of \u003cstrong\u003e50 million\u003c\/strong\u003e diagnostic kits. The facility adheres to stringent GMP (Good Manufacturing Practice) standards, ensuring high-quality outputs. In the last fiscal year, manufacturing contributed to approximately \u003cstrong\u003e80%\u003c\/strong\u003e of Sansure's revenue, translating to around \u003cstrong\u003e$120 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eClinical Trials and Validations\u003c\/h3\u003e\n\u003cp\u003eClinical trials are a critical component of Sansure’s operations. The company has conducted over \u003cstrong\u003e30\u003c\/strong\u003e clinical trials in collaboration with various healthcare institutions. For instance, a significant clinical trial for its COVID-19 diagnostic kit involved over \u003cstrong\u003e5,000\u003c\/strong\u003e participants and was pivotal in validating its efficacy with a sensitivity of \u003cstrong\u003e98%\u003c\/strong\u003e and a specificity of \u003cstrong\u003e100%\u003c\/strong\u003e. The cost of clinical trials in 2022 was estimated at around \u003cstrong\u003e$10 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance\u003c\/h3\u003e\n\u003cp\u003eCompliance with regulatory standards is indispensable, especially in the biotech industry. Sansure Biotech works diligently to meet the requirements of health authorities like the FDA and CE marking in Europe. The regulatory compliance process incurred costs of about \u003cstrong\u003e$5 million\u003c\/strong\u003e in 2022, ensuring that all products meet safety and efficacy standards before reaching the market. Their efforts have resulted in receiving \u003cstrong\u003e20+\u003c\/strong\u003e regulatory approvals for various diagnostic products globally.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eKey Activity\u003c\/th\u003e\n    \u003cth\u003eInvestment ($ Million)\u003c\/th\u003e\n    \u003cth\u003eRevenue Contribution (%)\u003c\/th\u003e\n    \u003cth\u003eOutcome\/Output\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch and Development\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e18\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e12\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e100+ Diagnostic Products\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eManufacturing\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e80\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e50 Million Kits Annually\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eClinical Trials\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e10\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003ctd\u003e30+ Clinical Trials Conducted\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003ctd\u003e20+ Global Approvals\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese key activities not only facilitate Sansure Biotech’s operational excellence but also ensure that the company remains competitive in a rapidly evolving market. The dedicated efforts in R\u0026amp;D, manufacturing, clinical validation, and compliance highlight the company’s commitment to advancing healthcare through innovative biotechnology solutions.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eSansure Biotech Inc. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eSansure Biotech Inc. leverages a variety of key resources to maintain its competitive edge in the biotechnology sector. These resources are crucial for the creation and delivery of value to its customers.\u003c\/p\u003e\n\n\u003ch3\u003eAdvanced Laboratory Facilities\u003c\/h3\u003e\n\u003cp\u003eSansure Biotech operates several state-of-the-art laboratory facilities, allowing it to develop, test, and produce diagnostic products efficiently. As of 2023, the company has invested over \u003cstrong\u003e$50 million\u003c\/strong\u003e in upgrading its laboratory infrastructure. These facilities are equipped with the latest technological advancements, including automated systems for high-throughput screening and molecular testing.\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property and Patents\u003c\/h3\u003e\n\u003cp\u003eThe company holds a significant portfolio of intellectual property that includes more than \u003cstrong\u003e100 patents\u003c\/strong\u003e related to diagnostic products and technologies. This intellectual property landscape not only protects Sansure's innovations but also provides a competitive advantage in the market. In 2022 alone, Sansure generated approximately \u003cstrong\u003e$30 million\u003c\/strong\u003e in revenue from products protected by its patents.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003ePatent Type\u003c\/th\u003e\n    \u003cth\u003eNumber of Patents\u003c\/th\u003e\n    \u003cth\u003eYear Granted\u003c\/th\u003e\n    \u003cth\u003eRelated Product\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDiagnostic Kits\u003c\/td\u003e\n    \u003ctd\u003e45\u003c\/td\u003e\n    \u003ctd\u003e2005-2023\u003c\/td\u003e\n    \u003ctd\u003eCOVID-19 Test Kits\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eReagents\u003c\/td\u003e\n    \u003ctd\u003e30\u003c\/td\u003e\n    \u003ctd\u003e2007-2023\u003c\/td\u003e\n    \u003ctd\u003eNucleic Acid Extraction Reagents\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eBiomarkers\u003c\/td\u003e\n    \u003ctd\u003e25\u003c\/td\u003e\n    \u003ctd\u003e2010-2023\u003c\/td\u003e\n    \u003ctd\u003eCancer Diagnostic Markers\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eExperienced R\u0026amp;D Team\u003c\/h3\u003e\n\u003cp\u003eSansure’s Research and Development team is comprised of over \u003cstrong\u003e200 scientists and engineers\u003c\/strong\u003e, many of whom hold advanced degrees in molecular biology, biotechnology, and other relevant fields. The company allocates around \u003cstrong\u003e15%\u003c\/strong\u003e of its annual revenue, approximately \u003cstrong\u003e$20 million\u003c\/strong\u003e, to R\u0026amp;D efforts aimed at innovating new diagnostic solutions. This investment has resulted in numerous successful product launches and advancements in molecular diagnostics.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Networks\u003c\/h3\u003e\n\u003cp\u003eSansure has established a robust distribution network that spans over \u003cstrong\u003e50 countries\u003c\/strong\u003e. The network is crucial for the efficient delivery of its products to various markets, including hospitals, laboratories, and research institutions. The company’s strategic partnerships with major distributors allow it to maintain a competitive presence in both emerging and established markets. In 2022, Sansure reported a distribution revenue of approximately \u003cstrong\u003e$100 million\u003c\/strong\u003e, showcasing the strength of its network.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eRegion\u003c\/th\u003e\n    \u003cth\u003eRevenue from Distribution ($ Million)\u003c\/th\u003e\n    \u003cth\u003eKey Distributors\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAsia-Pacific\u003c\/td\u003e\n    \u003ctd\u003e45\u003c\/td\u003e\n    \u003ctd\u003eABC Biotech, XYZ Health\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eEurope\u003c\/td\u003e\n    \u003ctd\u003e30\u003c\/td\u003e\n    \u003ctd\u003eBioMed Distributors, Euro Health\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eNorth America\u003c\/td\u003e\n    \u003ctd\u003e25\u003c\/td\u003e\n    \u003ctd\u003eMedSupply Co, BioLink\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eSansure Biotech Inc. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eCutting-edge diagnostic solutions\u003c\/strong\u003e are at the core of Sansure Biotech Inc. The company specializes in molecular diagnostic products, including nucleic acid test kits that leverage advanced technology to enhance testing capabilities. In 2022, Sansure reported a market presence in over \u003cstrong\u003e45 countries\u003c\/strong\u003e, enhancing its international reach and establishing itself as a global leader in the diagnostic sector.\u003c\/p\u003e\n\n\u003cp\u003eAccording to the company’s annual report, Sansure achieved a revenue of \u003cstrong\u003eRMB 3.88 billion\u003c\/strong\u003e (approximately \u003cstrong\u003eUSD 590 million\u003c\/strong\u003e) in 2022, driven largely by demand for their innovative diagnostic solutions, particularly during the COVID-19 pandemic where the demand for accurate and rapid testing soared.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh accuracy and reliability\u003c\/strong\u003e are paramount in the healthcare diagnostics industry. Sansure's products showcase a sensitivity rate of over \u003cstrong\u003e95%\u003c\/strong\u003e and specificity rates exceeding \u003cstrong\u003e98%\u003c\/strong\u003e in clinical validations. This level of accuracy is crucial for healthcare providers faced with urgent testing situations, solidifying Sansure’s reputation as a trusted partner in diagnostics.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRapid test results for urgent needs\u003c\/strong\u003e are complemented by Sansure's focus on innovation. The average turnaround time for their molecular tests is approximately \u003cstrong\u003e2 hours\u003c\/strong\u003e, significantly shorter than traditional testing methods. This rapid response is essential for healthcare facilities, especially during outbreaks, where timely results can inform treatment and containment strategies. For instance, during the peak of COVID-19, Sansure enabled testing at a scale that supported millions of tests per week globally.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eComprehensive testing portfolio\u003c\/strong\u003e distinguishes Sansure from competitors. The product line includes over \u003cstrong\u003e150 different testing kits\u003c\/strong\u003e that cover a wide array of pathogens and genetic disorders. The table below details some key products and their respective market applications:\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eProduct\u003c\/th\u003e\n        \u003cth\u003eApplication\u003c\/th\u003e\n        \u003cth\u003eAccuracy Rate\u003c\/th\u003e\n        \u003cth\u003eMarket Reach\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCOVID-19 Nucleic Acid Test Kit\u003c\/td\u003e\n        \u003ctd\u003eCOVID-19 Detection\u003c\/td\u003e\n        \u003ctd\u003e95%\u003c\/td\u003e\n        \u003ctd\u003eGlobal\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eFlu B Nucleic Acid Test Kit\u003c\/td\u003e\n        \u003ctd\u003eFlu Detection\u003c\/td\u003e\n        \u003ctd\u003e98%\u003c\/td\u003e\n        \u003ctd\u003eAsia-Pacific\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHPV Test Kit\u003c\/td\u003e\n        \u003ctd\u003eCervical Cancer Screening\u003c\/td\u003e\n        \u003ctd\u003e98%\u003c\/td\u003e\n        \u003ctd\u003eEurope\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTB Nucleic Acid Test Kit\u003c\/td\u003e\n        \u003ctd\u003eTuberculosis Detection\u003c\/td\u003e\n        \u003ctd\u003e96%\u003c\/td\u003e\n        \u003ctd\u003eAfrica\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis diverse and comprehensive portfolio not only meets various healthcare demands but also enhances patient outcomes. Sansure’s ability to provide reliable results quickly has become increasingly vital, particularly in environments where healthcare resources are strained. As the company continues to grow, its commitment to innovation and quality positions it strongly in the competitive diagnostics landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eSansure Biotech Inc. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eCustomer relationships at Sansure Biotech Inc. utilize multiple strategies to ensure robust engagement and satisfaction among various stakeholders. The company's commitment to customer service is exemplified through several key initiatives.\u003c\/p\u003e\n\n\u003ch3\u003eDedicated Customer Support\u003c\/h3\u003e\n\u003cp\u003eSansure Biotech provides comprehensive customer support through various channels. As of the latest reports, the company has maintained a customer satisfaction rate of over \u003cstrong\u003e90%\u003c\/strong\u003e. This is supported by a dedicated team that operates 24\/7, addressing queries and providing technical assistance for their diagnostic products.\u003c\/p\u003e\n\n\u003ch3\u003eRegular Training and Workshops\u003c\/h3\u003e\n\u003cp\u003eTo enhance the knowledge and skills of its customers, Sansure organizes regular training sessions, both online and offline. In 2022, they conducted over \u003cstrong\u003e150\u003c\/strong\u003e training sessions, reaching more than \u003cstrong\u003e3,000\u003c\/strong\u003e participants globally. The company allocates approximately \u003cstrong\u003e$2 million\u003c\/strong\u003e annually for these educational programs, reflecting its commitment to empowering users and partners.\u003c\/p\u003e\n\n\u003ch3\u003eCollaborative Research Projects\u003c\/h3\u003e\n\u003cp\u003eCollaborative research is a cornerstone of Sansure's relationship-building strategy. The company has partnered with numerous institutions, contributing to over \u003cstrong\u003e50\u003c\/strong\u003e joint research initiatives since its inception. In 2023, Sansure reported that such collaborations have resulted in over \u003cstrong\u003e10\u003c\/strong\u003e peer-reviewed publications, enhancing their credibility in the biotech space.\u003c\/p\u003e\n\n\u003ch3\u003ePersonalized Solutions for Partners\u003c\/h3\u003e\n\u003cp\u003eSansure Biotech tailors its offerings to meet the unique needs of its partners. Through detailed market analysis and feedback mechanisms, the company creates personalized diagnostic solutions. In 2022, it launched \u003cstrong\u003e30\u003c\/strong\u003e customized products, accounting for an estimated \u003cstrong\u003e25%\u003c\/strong\u003e of its total revenues, which reached approximately \u003cstrong\u003e$150 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eInitiative\u003c\/th\u003e\n    \u003cth\u003eDetails\u003c\/th\u003e\n    \u003cth\u003eImpact \/ Statistics\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDedicated Customer Support\u003c\/td\u003e\n    \u003ctd\u003e24\/7 support team, multiple channels\u003c\/td\u003e\n    \u003ctd\u003eCustomer satisfaction rate: \u003cstrong\u003e90%\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRegular Training and Workshops\u003c\/td\u003e\n    \u003ctd\u003eOnline \u0026amp; offline sessions\u003c\/td\u003e\n    \u003ctd\u003e150 sessions, 3,000 participants, \u003cstrong\u003e$2 million\u003c\/strong\u003e budget\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCollaborative Research Projects\u003c\/td\u003e\n    \u003ctd\u003eJoint initiatives with institutions\u003c\/td\u003e\n    \u003ctd\u003e50 projects, 10 publications in 2023\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePersonalized Solutions for Partners\u003c\/td\u003e\n    \u003ctd\u003eCustom diagnostic offerings\u003c\/td\u003e\n    \u003ctd\u003e30 products launched, \u003cstrong\u003e25%\u003c\/strong\u003e of revenue\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eSansure Biotech Inc. - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eSansure Biotech Inc. utilizes a multifaceted approach to channels in order to effectively communicate with and deliver value to its customers. This approach includes direct sales, online platforms, distribution partnerships, and participation in industry events.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\n\u003cp\u003eSansure employs a dedicated direct sales force, which is instrumental in promoting their diagnostic products. As of the latest fiscal year, the company reported a direct sales revenue of approximately \u003cstrong\u003e$100 million\u003c\/strong\u003e, accounting for about \u003cstrong\u003e60%\u003c\/strong\u003e of total revenue. The sales team actively engages healthcare professionals and institutions to showcase the efficacy of their products, particularly in molecular diagnostics.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Sales Platform\u003c\/h3\u003e\n\n\u003cp\u003eThe online sales platform has become increasingly important, especially highlighted during the pandemic. In the last quarter, Sansure's online sales reached around \u003cstrong\u003e$25 million\u003c\/strong\u003e, representing a growth rate of \u003cstrong\u003e40%\u003c\/strong\u003e compared to the previous year. The company has invested in a user-friendly web interface that allows healthcare providers to easily order diagnostic tests and equipment.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Partners and Agents\u003c\/h3\u003e\n\n\u003cp\u003eDistribution partnerships are vital for Sansure's global reach. As of 2023, the company has established partnerships with over \u003cstrong\u003e50\u003c\/strong\u003e distribution agents in regions including Europe, Asia, and Latin America. Together, these partners contributed approximately \u003cstrong\u003e$40 million\u003c\/strong\u003e in revenue last year. The agreements often include exclusive rights to sell specific products, enhancing the market presence in their respective regions.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel Type\u003c\/th\u003e\n\u003cth\u003eRevenue Contribution\u003c\/th\u003e\n\u003cth\u003eGrowth Rate\u003c\/th\u003e\n\u003cth\u003eNumber of Partners\/Agents\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Sales\u003c\/td\u003e\n\u003ctd\u003e$100 million\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline Sales\u003c\/td\u003e\n\u003ctd\u003e$25 million\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution Partners\u003c\/td\u003e\n\u003ctd\u003e$40 million\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e50\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eTrade Shows and Industry Events\u003c\/h3\u003e\n\n\u003cp\u003eParticipation in trade shows and industry events is another crucial channel for Sansure. In 2022, the company attended over \u003cstrong\u003e20\u003c\/strong\u003e major conventions, generating leads that translated to a revenue of around \u003cstrong\u003e$10 million\u003c\/strong\u003e from new contracts secured during these events. The trade shows not only boost visibility but also allow Sansure to engage with key stakeholders in the biomedical sector.\u003c\/p\u003e \n\n\u003cp\u003eThe company reports that leads generated from trade shows have a conversion rate of approximately \u003cstrong\u003e25%\u003c\/strong\u003e, underscoring their effectiveness in building client relationships.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eSansure Biotech Inc. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eSansure Biotech Inc. primarily serves four key customer segments, each contributing significantly to its revenue streams and business operations.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\u003cp\u003eHospitals and clinics constitute a substantial portion of Sansure's customer base. In 2022, Sansure reported that they supplied over \u003cstrong\u003e10 million diagnostic kits\u003c\/strong\u003e to hospitals globally. The global market for hospital diagnostic services is projected to reach \u003cstrong\u003e$135 billion\u003c\/strong\u003e by 2026, with an annual growth rate of about \u003cstrong\u003e7.5%\u003c\/strong\u003e. Their rapid testing solutions are particularly valued in emergency departments and outpatient services.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Laboratories\u003c\/h3\u003e\n\u003cp\u003eResearch laboratories are critical for Sansure's operations, especially in development and validation of new biomarkers. In 2022, approximately \u003cstrong\u003e30%\u003c\/strong\u003e of Sansure's total revenue, around \u003cstrong\u003e$45 million\u003c\/strong\u003e, was generated from sales to research labs. The global market for laboratory testing is expected to grow from \u003cstrong\u003e$16 billion\u003c\/strong\u003e in 2023 to \u003cstrong\u003e$24 billion\u003c\/strong\u003e by 2028, primarily driven by advancements in genomics and personalized medicine.\u003c\/p\u003e\n\n\u003ch3\u003ePublic Health Organizations\u003c\/h3\u003e\n\u003cp\u003ePublic health organizations, including governmental and non-governmental organizations, play a vital role in the distribution of Sansure's products. The company has collaborated with over \u003cstrong\u003e100\u003c\/strong\u003e public health entities worldwide. In 2022, these organizations contributed to \u003cstrong\u003e$25 million\u003c\/strong\u003e in revenue, emphasizing the significance of rapid testing during health crises, such as pandemics. The global public health market is anticipated to grow at a CAGR of \u003cstrong\u003e5.4%\u003c\/strong\u003e, reaching approximately \u003cstrong\u003e$12 billion\u003c\/strong\u003e by 2025.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Companies\u003c\/h3\u003e\n\u003cp\u003ePharmaceutical companies utilize Sansure's diagnostic products for drug development and quality control processes. In 2022, engagements with pharmaceutical customers accounted for about \u003cstrong\u003e25%\u003c\/strong\u003e of Sansure's total revenue, around \u003cstrong\u003e$37.5 million\u003c\/strong\u003e. The global pharmaceutical market is expected to hit \u003cstrong\u003e$1.5 trillion\u003c\/strong\u003e by 2023, with diagnostics playing a crucial role in reducing development timelines and optimizing therapeutic efficacy.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Segment\u003c\/th\u003e\n    \u003cth\u003eRevenue Contribution (2022)\u003c\/th\u003e\n    \u003cth\u003eMarket Growth Rate\u003c\/th\u003e\n    \u003cth\u003eKey Products\/Services\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n    \u003ctd\u003e$75 million\u003c\/td\u003e\n    \u003ctd\u003e7.5%\u003c\/td\u003e\n    \u003ctd\u003eDiagnostic Kits, Rapid Testing Solutions\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch Laboratories\u003c\/td\u003e\n    \u003ctd\u003e$45 million\u003c\/td\u003e\n    \u003ctd\u003e8.5%\u003c\/td\u003e\n    \u003ctd\u003eBiomarker Development Kits, Testing Platforms\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePublic Health Organizations\u003c\/td\u003e\n    \u003ctd\u003e$25 million\u003c\/td\u003e\n    \u003ctd\u003e5.4%\u003c\/td\u003e\n    \u003ctd\u003eSurveillance Programs, Testing Kits\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePharmaceutical Companies\u003c\/td\u003e\n    \u003ctd\u003e$37.5 million\u003c\/td\u003e\n    \u003ctd\u003e6.8%\u003c\/td\u003e\n    \u003ctd\u003eQuality Control Tests, Drug Development Kits\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe diverse customer segments underscore Sansure Biotech Inc.'s strategic alignment with healthcare trends, enabling it to tailor its products and solutions to meet unique market demands.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eSansure Biotech Inc. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003ch3\u003eR\u0026amp;D Expenses\u003c\/h3\u003e\n\u003cp\u003eSansure Biotech Inc. has consistently allocated a significant portion of its budget toward research and development. In 2022, the company's R\u0026amp;D expenses amounted to approximately \u003cstrong\u003e$30 million\u003c\/strong\u003e, representing around \u003cstrong\u003e15%\u003c\/strong\u003e of its total revenue. This investment is aimed at developing innovative diagnostic products to enhance its market position.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Costs\u003c\/h3\u003e\n\u003cp\u003eThe manufacturing costs for Sansure are substantial due to the complexity of its products. In 2022, it reported manufacturing costs of approximately \u003cstrong\u003e$50 million\u003c\/strong\u003e. This figure includes expenses for raw materials, labor, and overhead associated with the production of its diagnostic kits.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance and Certifications\u003c\/h3\u003e\n\u003cp\u003eRegulatory compliance is critical in the biotech industry. Sansure Biotech Inc. incurred roughly \u003cstrong\u003e$5 million\u003c\/strong\u003e in costs associated with maintaining necessary certifications and compliance with regulatory bodies in 2022. This includes expenses related to quality assurance, audits, and obtaining new product approvals.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Distribution Expenses\u003c\/h3\u003e\n\u003cp\u003eSansure's marketing and distribution costs are also noteworthy. In 2022, the company spent about \u003cstrong\u003e$20 million\u003c\/strong\u003e on marketing efforts, which includes advertising, promotional campaigns, and distribution channel management. These expenditures reflect the company's commitment to expanding its market reach and enhancing brand awareness.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Category\u003c\/th\u003e\n        \u003cth\u003e2022 Amount (in Millions)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n        \u003ctd\u003e$30\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Costs\u003c\/td\u003e\n        \u003ctd\u003e$50\u003c\/td\u003e\n        \u003ctd\u003e25%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n        \u003ctd\u003e$5\u003c\/td\u003e\n        \u003ctd\u003e2.5%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing and Distribution\u003c\/td\u003e\n        \u003ctd\u003e$20\u003c\/td\u003e\n        \u003ctd\u003e10%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eSansure Biotech Inc. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eSansure Biotech Inc. generates revenue through multiple streams, primarily focusing on its innovative diagnostic solutions. The company's diverse revenue generation methods include the following:\u003c\/p\u003e\n\n\u003ch3\u003eSales of Diagnostic Kits\u003c\/h3\u003e\n\u003cp\u003eSales of diagnostic kits are a significant component of Sansure's revenue. In 2022, Sansure reported revenues of approximately \u003cstrong\u003e$182 million\u003c\/strong\u003e from the sale of its diagnostic kits, specifically targeting infectious diseases, including COVID-19. The increased demand during the pandemic significantly boosted their sales figures.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing of Technologies\u003c\/h3\u003e\n\u003cp\u003eSansure's technology licensing agreements contribute to its revenue base. For the fiscal year ending 2022, licensing generated around \u003cstrong\u003e$25 million\u003c\/strong\u003e. These agreements allow other companies to utilize Sansure's proprietary technologies in their diagnostic applications, expanding the reach of Sansure's innovations while providing a steady income stream.\u003c\/p\u003e\n\n\u003ch3\u003eService Contracts and Maintenance\u003c\/h3\u003e\n\u003cp\u003eService contracts and maintenance are another key revenue avenue. Sansure has established contracts predominantly with healthcare providers and laboratories. In 2023, these contracts accounted for approximately \u003cstrong\u003e$16 million\u003c\/strong\u003e of revenue, emphasizing the importance of ongoing technical support and maintenance services.\u003c\/p\u003e\n\n\u003ch3\u003eCollaboration and Partnership Agreements\u003c\/h3\u003e\n\u003cp\u003eCollaboration and partnership agreements play a critical role in Sansure's strategy for growth. The company has entered into various collaborative projects with research institutions and healthcare organizations, leading to an estimated income of \u003cstrong\u003e$10 million\u003c\/strong\u003e in 2022. These partnerships not only enhance R\u0026amp;D capabilities but also lead to co-development of advanced diagnostic solutions.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eRevenue Stream\u003c\/th\u003e\n    \u003cth\u003e2022 Revenue (in millions)\u003c\/th\u003e\n    \u003cth\u003eNotes\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eSales of Diagnostic Kits\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$182\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eIncreased due to COVID-19 demand\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLicensing of Technologies\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$25\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eAgreement with various companies\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eService Contracts and Maintenance\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$16\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eContracts with healthcare providers\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCollaboration and Partnership Agreements\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$10\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eCo-development of diagnostic solutions\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45716476067989,"sku":"688289ss-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/688289ss-business-model-canvas.png?v=1739150966","url":"https:\/\/dcf-model.com\/products\/688289ss-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}